Psoriasis is a visible condition. That makes it different from most chronic diseases. You can't conceal a psoriasis flare on your hands, face, or scalp the way you can conceal hypertension or diabetes. For many people, the emotional impact of the diagnosis is as significant as the physical symptoms.
The honest first thing to say: for most people, psoriasis is very manageable, and many people with psoriasis live entirely normal lives with minimal disruption. The second thing: a small proportion of patients have severe, biologically driven disease that requires expensive medications — and the South African medical aid system does not make this easy. Knowing which category you're likely in, and what your scheme can and cannot do, is the starting point.
What to Do Right Now: Five Steps
Step 1 — Establish your psoriasis type and severity
Not all psoriasis is the same. Mild plaque psoriasis on the elbows, managed with topical creams, is a completely different proposition from erythrodermic psoriasis requiring hospitalisation. The key markers your dermatologist will assess: - PASI score (Psoriasis Area and Severity Index): < 10 is mild; > 20 is severe - Body surface area (BSA): Percentage of skin affected - DLQI (quality-of-life impact): Scalp, nail, genital, and palmoplantar psoriasis often score high on DLQI even with modest PASI
If your PASI is below 10 and your quality-of-life impact is manageable, topical treatment is appropriate and you are unlikely to need systemic therapy. If PASI > 10 or your quality of life is significantly affected, the systemic pathway becomes relevant.
Step 2 — Start with topicals and understand what they do
Topical treatment is first-line for all psoriasis. Key agents: - Calcipotriol/betamethasone (Daivobet): A combination of a vitamin D analogue and a corticosteroid — the most effective single topical for plaque psoriasis. Apply once daily. ~R600/month. - Potent topical corticosteroids (betamethasone dipropionate): Effective for acute flares. Avoid prolonged use on thin skin (face, flexures) to prevent atrophy. - Coal tar: Older agent but effective, particularly for scalp psoriasis. Cosmetically challenging. - Salicylic acid: Use first to remove scale before applying other topicals — they penetrate much better onto de-scaled skin.
Topicals funded from d2d benefit. Not CDL. No chronic registration needed.
Step 3 — Understand phototherapy as your next step before systemic therapy
Narrowband UVB phototherapy (nbUVB) is highly effective for moderate psoriasis and is significantly cheaper than systemic or biologic therapy. If your psoriasis is moderately severe but does not yet meet criteria for systemic treatment, phototherapy is worth pursuing before escalating to methotrexate or biologics. Three sessions per week, typically for 8–12 weeks. Available at dermatology centres in major SA cities.
Practical note: phototherapy requires travel to a centre three times a week, which is not practical for everyone. If this is a constraint, discuss whether methotrexate would be a more practical alternative.
Step 4 — Know the systemic therapy sequence and where costs escalate
For psoriasis requiring systemic therapy, the sequence is: 1. Methotrexate (~R200/month): Safe, inexpensive, and effective for many patients. The standard first systemic in SA. Requires regular blood monitoring. 2. Phototherapy (if not tried): See Step 3. 3. Cyclosporine (~R1,800/month): Faster-acting but not for long-term use. Useful for rapid disease control. 4. Biologics (R120,000–R200,000/year): Anti-IL-17, anti-IL-23, or anti-TNF agents. Highly effective but expensive and NOT CDL-funded.
The escalation cliff is between Step 3 and biologics. Methotrexate costs R2,400/year. The cheapest biologic (adalimumab biosimilar) costs approximately R60,000/year. There is no mandatory scheme funding for psoriasis biologics. This is the most important financial fact in this article.
Step 5 — Watch for psoriatic arthritis
Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA) — joint inflammation, usually involving the fingers, toes, or sacroiliac joints. Symptoms: swollen, painful joints; morning stiffness; sausage-like swelling of a whole finger or toe (dactylitis); heel pain (enthesitis).
If you develop any joint symptoms, tell your dermatologist and ask for a rheumatology referral. PsA is important not just because it causes joint damage — it changes the financial landscape. PsA may be covered under the Chronic Disease List (CDL) as an inflammatory arthritis, which unlocks biologic funding through the CDL exceptional needs pathway. Early diagnosis of PsA is both clinically and financially important.
Your Most Important Questions, Answered
Is psoriasis curable? No — psoriasis is a lifelong condition. But it can achieve very long periods of remission, particularly with biologics. Some patients on biologics maintain clear skin for years.
Is it contagious? No. Psoriasis is an immune-mediated disease, not an infection. It cannot be transmitted by contact.
Do I need to register for a CDL benefit? No. Psoriasis is not on the Chronic Disease List. There is no CDL registration. Topicals are claimed from d2d benefit; systemic therapy (MTX) is typically pre-authorised through your scheme's formulary process.
What if my scheme won't fund my biologic? This is the most common frustration for severe psoriasis patients. Options: - Appeal the exceptional needs decision with your dermatologist providing clinical motivation - Request biosimilar adalimumab (cheapest biologic option) — some schemes are more willing to approve this - Ask whether PsA has developed — if so, the CDL pathway may be available - Manufacturer patient assistance programmes may be available for some biologics
Should I change my scheme? If you are at or approaching biologic therapy, yes — scheme selection becomes very important. Schemes with established dermatology biologic exceptional needs programmes offer materially better access than those without them.
Your Scheme Coverage for Psoriasis
Psoriasis topicals and dermatologist consultations are claimed from d2d benefit. There is no CDL registration. Systemic therapy (methotrexate) typically requires pre-authorisation. Biologics require exceptional needs authorisation — and this is not guaranteed. Your scheme is not legally required to fund psoriasis biologics the way it is required to fund CDL medications.
If your psoriasis is mild-to-moderate and well controlled on topicals or methotrexate, scheme selection is not driven by your psoriasis. If you need or may need biologic therapy, scheme selection becomes critical. AURA can help you assess this.
Ready to check what your scheme covers for psoriasis? Run your AURA check